Curated News
By: NewsRamp Editorial Staff
December 02, 2025
CTT Pharma Unveils 2026 Manufacturing Plans for Revolutionary Drug Delivery Tech
TLDR
- CTT Pharma's patented micelle technology offers a competitive edge in drug delivery, with manufacturing plans for 2026 and SEC reporting to attract more investors.
- CTT Pharma will file an S-1 for funding, use capital for manufacturing, hire regulatory experts, and locate a production facility in Q1 2026.
- CTT Pharma's technology aims to improve oral drug delivery, potentially enhancing healthcare accessibility and offering a smoking cessation alternative through a Johns Hopkins partnership.
- CTT Pharma's scientific paper on micelle strip technology will be published on December 15, 2025, increasing visibility and scientific understanding.
Impact - Why it Matters
This news matters because CTT Pharma's micelle thin-film technology represents a significant advancement in oral drug delivery, potentially transforming how medications and supplements are administered. For consumers, this could mean faster-acting, more convenient treatments without traditional pills or injections, particularly for nicotine cessation and vitamin supplementation. For investors, the company's transition to SEC reporting status increases transparency and credibility, while the NIH partnership and scientific publication validate the technology's potential. In the broader pharmaceutical industry, successful commercialization could disrupt existing delivery methods, offering more efficient alternatives that improve patient compliance and outcomes.
Summary
CTT Pharma's CEO Ryan Khouri has issued an optimistic letter to shareholders outlining the company's strategic roadmap for 2026, emphasizing their patented micelle thin-film technology as a game-changer in drug delivery. The company plans to begin manufacturing micelle-encapsulated vitamin supplements, bioactive supplement strips, and nicotine oral strips next year, leveraging their unique oral dissolvable strip platform that promises faster and more convenient medication delivery. CTT is in the final stages of preparing an S-1 filing to become an SEC reporting company, which will provide greater transparency and potentially attract more investors through an equity line of credit (ELOC) to fund manufacturing expansion.
Key developments include strengthening the team with regulatory experts and commercial product specialists, securing a manufacturing facility in early 2026, and advancing their partnership with Johns Hopkins University for an NIH-funded smoking cessation study. A significant scientific milestone was achieved with the acceptance of a peer-reviewed manuscript by Dr. Katharine Cole and founder Dr. Pankaj Modi for publication on December 15, 2025, which will enhance visibility and understanding of their technology. The company's progress is detailed in the original release on www.newmediawire.com, where shareholders can find comprehensive updates.
Khouri emphasizes careful management of share dilution while pursuing commercialization pathways, with manufacturing plans proceeding independently of the NIH grant decision timeline. The company anticipates holding a conference call in Q1 2026 to discuss initiatives and further strengthen their patent portfolio, positioning CTT as a formidable player in the pharmaceutical innovation space with tangible near-term goals.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, CTT Pharma Unveils 2026 Manufacturing Plans for Revolutionary Drug Delivery Tech
